The Implementation of Pre-exposure Prophylaxis of Injectable Cabotegravir
Status:
Not yet recruiting
Trial end date:
2026-02-01
Target enrollment:
Participant gender:
Summary
Although CAB LA PrEP has been proven efficacious in blinded randomized controlled clinical
trials, additional research is needed to evaluate effectiveness in real world settings as
well as to identify effective implementation strategies. The proposed implementation study
will assess the safety and effectiveness of open label CAB LA PrEP when offered at public
health facilities to cisgender men and transgender or gender non-binary individuals who have
sex with persons assigned male at birth. The study will also evaluate two nested
implementation strategies, an mHealth education and decision support tool and a WhatsApp
injection appointment reminder. The study will also assess overall facilitators and barriers
to integrating CAB LA into existing oral PrEP services.
Phase:
Phase 3
Details
Lead Sponsor:
Evandro Chagas National Institute of Infectious Disease
Collaborators:
Beatriz Grinsztejn Brenda Hoagland Thiago Torres Valdilea Gonçalves